Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Merck & Co.'s Idvynso (doravirine/islatravir) wins FDA approval for virologically suppressed adults with human immunodeficiency virus following Ph3 success
Small molecule, infectious disease, combination therapy, HIV, reverse transcriptase inhibitor - Read more

Foundation Medicine, Bristol Myers Squibb expand collaboration on FoundationOne CDx for MTAP deletion detection
Co-development, oncology, diagnostics, biomarkers, companion diagnostic - Read more

Crown Bioscience, Turbine partner to integrate AI-driven virtual assays with tumor organoid validation in translational oncology
Research collaboration, oncology, AI/ML, drug discovery, diagnostics - Read more

GC Biopharma, Galux collaborate on AI-designed antibody therapeutics targeting autoimmune diseases
Research collaboration, autoimmune, AI/ML, antibody, co-development - Read more

Struggling with your sales & marketing stack as you’re selling into biotech & life sciences? We’re here to help with a free webinar.

Come learn the importance of brand establishment, proper segmentation of your target ICP, thought leadership content development, omnichannel approaches to outreach campaigns, and personalized, high-touch outreach.

Presented by Hapatune, a boutique marketing firm for bioprocess and life science companies, and Science 2 Sales, a lead-gen and GTM agency helping companies sell into biotech, life sciences, and pharma.

Grab your spot before it’s all filled out!

AstraZeneca's Ultomiris (ravulizumab) meets primary endpoint in Ph3 trial for immunoglobulin A nephropathy
Antibody, autoimmune, monoclonal antibody, IgA nephropathy, complement inhibitor, rare disease - Read more

BioAge Labs' BGE-102 (BGE-102) shows Ph1 promise in cardiovascular risk via NLRP3 inhibition, Ph2 planned
Small molecule, cardiovascular, NLRP3 inhibitor, atherosclerotic cardiovascular disease, inflammation - Read more

Roche's Enspryng (satralizumab) meets Ph3 primary endpoint in myelin oligodendrocyte glycoprotein antibody-associated disease, global submissions planned
Antibody, autoimmune, monoclonal antibody, MOGAD, IL-6 receptor, neurological - Read more

Dayspring Pharma's CG2001 (minoxidil/finasteride) meets Ph2 primary endpoint in androgenetic alopecia in Chinese adult men
Small molecule, dermatological, combination therapy, androgenetic alopecia, minoxidil, finasteride - Read more

Johnson & Johnson and Legend Biotech's Carvykti (ciltacabtagene autoleucel) shows Ph2 promise in high-risk smoldering multiple myeloma
Cell therapy, cancer, CAR-T, multiple myeloma, smoldering multiple myeloma, BCMA target - Read more

Flagship Pioneering launches Serif Biomedicines with $50M to develop novel modified DNA genetic medicines
Gene therapy, rare disease, financial, strategic - Read more

Tortugas Neuroscience debuts with $106M seed and Series A for CNS disorders
Neurological, small molecule, clinical-stage, schizophrenia, epilepsy - Read more

Ray Therapeutics raises $125M Series B for genetic retinal degeneration gene therapy
Gene therapy, ophthalmology, rare disease, retinal degeneration, clinical-stage - Read more

Lumira Ventures holds first closing of Fund V, targeting $200M for biotech and medtech
Venture capital, biotechnology, medical device, healthcare investment - Read more

Spruce Biosciences prices $60M public offering for neurological disorder therapies development
Neurological, rare disease, clinical-stage, small molecule - Read more

Amazon One Medical launches all-in-one GLP-1 weight management programme bundling primary care, pharmacy, and virtual care
GLP-1, obesity, competitive, strategic - Read more

Vidac Pharma Holdings evaluates continental European expansion into France, Germany, and Switzerland via spin-off entity
Small molecule, oncology, strategic, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Merck & Co.’s Welireg (belzutifan) Ph3 trial misses dual endpoints in first-line clear cell renal cell carcinoma
Small molecule, cancer, combination therapy, renal cell carcinoma, HIF-2α inhibitor, PD-1 inhibitor - Read more

Novartis drops two Ph3 (abelacimab) programs for cancer-related thrombosis after inferior efficacy observed
Small molecule, cardiovascular, anticoagulant, factor XI inhibitor, atrial fibrillation, cancer-associated thrombosis - Read more [Paywall]

Replimune cuts 224 Massachusetts jobs after FDA's second rejection of melanoma drug RP1
Oncolytic virus, oncology, regulatory, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here